Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
31 October 2018Website:
http://www.axonics.comNext earnings report:
26 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
AXNX Latest News
Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.
Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ago.
Invest in companies like Axonics (AXNX), Enerpac Tool Group (EPAC), Cardinal Health (CAH) and Acuity Brands (AYI) due to higher efficiency levels.
Axonics has agreed to be acquired by Boston Scientific for $71 per share in cash. Assuming the deal receives the approval of shareholders and regulators, it should close in the first half of 2024.
Axonics (NASDAQ: AXNX ) stock is rising higher on Monday following news that Boston Scientific (NYSE: BSX ) is acquiring the company for $3.7 billion. That has Boston Scientific agreeing to purchase Axonics for $71 in cash per share.
The shares of Axonix Inc (NASDAQ:AXNX) are soaring today, after news that Boston Scientific (BSX) is acquiring the medical equipment name for approximately $3.7 billion, or $71 per share.
The move will expand Boston's product portfolio in its urology business.
Boston Scientific said on Monday it had agreed to buy medtech company Axonics Inc for $3.7 billion.
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024. Interested parties may access a live webcast and replay of the presentation by visiting the Axonics investor relations website. About Axonics Axonics is a global medical techn.
- 1(current)
What type of business is Axonics?
Axonics, Inc., a medical technology company, is engaged in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary incontinence and frequency of urination, as well as fecal incontinence and non-obstructive urinary retention. Its patented rechargeable SNM system (r-SNM) delivers weak electrical impulses to the target sacral nerve to restore normal communication with the brain and from it, in order to reduce symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent for the treatment of stress urinary incontinence in women. The company was previously known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was registered in 2012, with its headquarters located in Irvine, California.
What sector is Axonics in?
Axonics is in the Healthcare sector
What industry is Axonics in?
Axonics is in the Medical Devices industry
What country is Axonics from?
Axonics is headquartered in United States
When did Axonics go public?
Axonics initial public offering (IPO) was on 31 October 2018
What is Axonics website?
https://www.axonics.com
Is Axonics in the S&P 500?
No, Axonics is not included in the S&P 500 index
Is Axonics in the NASDAQ 100?
No, Axonics is not included in the NASDAQ 100 index
Is Axonics in the Dow Jones?
No, Axonics is not included in the Dow Jones index
When does Axonics report earnings?
The next expected earnings date for Axonics is 26 July 2024